Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022-Reference-Cited by-同舟云学术

Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022

Published:2022-01-27 Issue:4 Volume:27 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Veneti Lamprini¹^ORCID,Bøås Håkon²,Bråthen Kristoffersen Anja³,Stålcrantz Jeanette⁴²,Bragstad Karoline⁵,Hungnes Olav⁵,Storm Margrethe Larsdatter⁶,Aasand Nina⁶,Rø Gunnar³,Starrfelt Jostein¹,Seppälä Elina²,Kvåle Reidar⁷⁸,Vold Line¹,Nygård Karin¹,Buanes Eirik Alnes⁹⁸,Whittaker Robert²

Affiliation:

1. Department of Infection Control and Preparedness, Norwegian Institute of Public Health, Oslo, Norway

2. Department of Infection Control and Vaccines, Norwegian Institute of Public Health, Oslo, Norway

3. Department of Method Development and Analytics, Norwegian Institute of Public Health, Oslo, Norway

4. European Program for Intervention Epidemiology Training, European Centre for Disease Prevention and Control, Stockholm, Sweden

5. Department of Virology, Norwegian Institute of Public Health, Oslo, Norway

6. Department of Infectious Disease Registries, Norwegian Institute of Public Health, Oslo, Norway

7. Department of Clinical Medicine, University of Bergen, Bergen, Norway

8. Department of Anaesthesia and Intensive Care, Haukeland University Hospital, Bergen, Norway

9. Norwegian Intensive Care and Pandemic Registry, Haukeland University Hospital, Bergen, Norway

Abstract

We included 39,524 COVID-19 Omicron and 51,481 Delta cases reported in Norway from December 2021 to January 2022. We estimated a 73% reduced risk of hospitalisation (adjusted hazard ratio: 0.27; 95% confidence interval: 0.20–0.36) for Omicron compared with Delta. Compared with unvaccinated groups, Omicron cases who had completed primary two-dose vaccination 7–179 days before diagnosis had a lower reduced risk than Delta (66% vs 93%). People vaccinated with three doses had a similar risk reduction (86% vs 88%).

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference15 articles.

1. Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021.;Brandal;Euro Surveill,2021

2. Norwegian Institute of Public Health (FHI). Ukerapport uke 2 (10.01 - 16.01.22): Ukerapporter om koronavirus og covid-19. [Weekly report week 2 (10–16 Jan 2022): Weekly reports about coronavirus and COVID-19]. Oslo: FHI; 2022. Norwegian. Available from: https://www.fhi.no/contentassets/8a971e7b0a3c4a06bdbf381ab52e6157/vedlegg/2022/ukerapport-uke-2-10.01---16.01.22.pdf

3. Norwegian Institute of Public Health (FHI). Ukerapport uke 52 (27.12.21 - 02.01.22): Ukerapporter om koronavirus og covid-19. [Weekly report week 52 (27 Dec 2021–2 Jan 2022): Weekly reports about coronavirus and COVID-19]. Oslo: FHI; 2022. Norwegian. Available from: https://www.fhi.no/contentassets/8a971e7b0a3c4a06bdbf381ab52e6157/vedlegg/2021/ukerapport-uke-52-27.12.21---02.01.22.pdf

4. Norwegian Institute of Public Health (FHI). Emergency preparedness register for COVID-19 (Beredt C19). Oslo: FHI; 2021. Available from: https://www.fhi.no/en/id/infectious-diseases/coronavirus/emergency-preparedness-register-for-covid-19

5. Statens Serum Institut (SSI). Status of the SARS-CoV-2 variant Omicron in Denmark. Copenhagen: SSI; 2022. Available from: https://files.ssi.dk/covid19/omikron/statusrapport/rapport-omikronvarianten-03012022-9gj3

Cited by 130 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Frequency and risk of SARS-CoV-2 reinfections in Norway: a nation-wide study, February 2020 to January 2022;BMC Public Health;2024-01-15

2. Pathogen evolution, prevention/control strategy and clinical features of COVID-19: experiences from China;Frontiers of Medicine;2023-12-29

3. Heterologous booster vaccines reduce severity and mortality in COVID-19 during BA.2 and BA.4/BA.5 omicron predominance in Thailand;Journal of Microbiology, Immunology and Infection;2023-12

4. Risk of hospital admission and death from first-ever SARS-CoV-2 infection by age group during the Delta and Omicron periods in British Columbia, Canada;Canadian Medical Association Journal;2023-10-29

5. Resurgence of SARS-CoV-2 Delta after Omicron variant superinfection in an immunocompromised pediatric patient;Virology Journal;2023-10-27